He arrived unannounced and unrehearsed — and that, it turned out, was exactly the right way to arrive.
Gregory Greenberg, DVP of Global Sales at AMETEK Brookfield, walked into Smart Labtech’s ASM 2026 afternoon session without a presentation deck, without a prepared script, and — by his own admission — without knowing he was going to be speaking. What followed was one of the most energising, frank, and commercially instructive interactions the Smart Labtech team had experienced in years. Accompanied by Rohan, Brookfield’s India regional manager, Greg held the room for well over an hour — part global strategy briefing, part sales coaching session, part Q&A, and entirely unscripted.
“I’m a little buzzing right now,” he said at the outset, with the easy confidence of someone who has run these conversations in boardrooms and distributor warehouses across five continents. “I didn’t even know I was doing this. But it’s fine. Let’s just talk.”
They talked. And what emerged from that conversation was a picture of where AMETEK Brookfield stands, where Smart Labtech fits within its global architecture, and — most importantly — where the real growth lies for the partnership in the year ahead.
AMETEK — The $8 Billion Machine Behind Brookfield
Greg opened with a question to the room: how big is AMETEK? Guesses ranged from $10 billion to $25 billion. The answer: $8 billion — a figure that places AMETEK among the world’s most significant industrial technology conglomerates, with approximately 140 operating companies spanning sensors, controls, test and measurement, and precision instrumentation across every conceivable industrial segment.
Brookfield — the ninety-two-year-old viscometry institution headquartered in Middleboro, Massachusetts — is one of those operating companies. With a FY2026 budget of $108 million and roughly 50% of its business generated through a completely direct model in the United States, Brookfield relies on approximately 75 distributors worldwide to deliver the remaining half. Smart Labtech is among those distributors — and, Greg made clear, one that carries genuine credibility.
“When you think of viscosity, you think of Brookfield,” he said. “It’s in so many formulas, so many method developments. It’s everywhere around the world.” That legacy — ninety-two years of being written into SOPs, regulatory submissions, and production line protocols globally — is both Brookfield’s greatest strength and its most important commercial asset. It creates residual business that flows naturally to distributors without requiring active selling. But it also creates a ceiling: if all you sell is what customers already know they want, you are permanently transactional.
The ceiling, Greg said plainly, is a problem he intends to solve.
The Paradigm Shift — From Push-Inventory to Sales-Out
Before getting to the growth agenda, Greg offered an unusually candid account of Brookfield’s recent distributor history. When AMETEK acquired Brookfield in 2016, the transition from family business to corporate discipline was, in his words, “a really hard impact on distributors.” The early post-acquisition years saw distributors pushed to hold significant inventory — but without the sales support infrastructure to move it. Inventory swelled. Sales-out did not keep pace.
“That’s not good for you guys, and it’s not good for us,” Greg said. “The emphasis now, around the world, is on selling — on sales-out. Not on how much inventory you’re holding.”
This reorientation is not merely philosophical. It is structural. The training programme that brought distributors to Brookfield’s Mumbai facility — which some Smart Labtech team members have attended — is part of this shift. So is the decision to redirect marketing-generated leads from Brookfield’s automation platform (Pardot, sitting on top of Salesforce) directly to distributors rather than to the direct sales team. “Our direct business is actually decreasing,” Greg noted, “and the distributor business is going the other way — which is good.”
The trust is being invested. The expectation is reciprocal.
The Growth Thesis — High-End Products Are the Only Answer
Greg’s core strategic argument was stated once and repeated several times in different forms: in a viscometer market growing at approximately 5% per year globally — a mature market with limited new demand — the only real growth vector for Smart Labtech is the high-end product portfolio. Not more viscometers. More rheometers. More texture analysers. More powder flow testers. More moisture analysers.
He drew the logic on the proverbial whiteboard: if you plot viscometer (DV) units over time, the line is essentially flat. The market replaces itself. You maintain the base, you earn the service, and you keep the pipeline full — but you do not grow in any meaningful sense. Add high-end products — RSX, RSO, CTX, ZTX, VPXL — and the growth line diverges dramatically upward.
The arithmetic Rohan offered was simple and compelling: one RSX or RSO rheometer is worth five times a standard viscometer in invoice value. Two high-end products in a quarter can achieve the same revenue contribution as ten viscometers. For a salesperson directly incentivised on targets, the path is clear: master the high-end, and the target becomes easier to hit, not harder.
A new addition to the Brookfield India team — an application specialist whose sole remit is high-end product support for all distributors — was announced as a direct response to distributor feedback. “You don’t have to be technical experts on everything,” Greg said. “Now you have a resource who knows the products inside and out, who can go with you to customers, who can have the application conversation. That’s what we heard from you. That’s what we built.”
The CompuTrack-VPXL Opportunity — Replacing Karl Fischer, One Lab at a Time
The single most commercially specific conversation of the session centred on moisture analysis — and specifically on Brookfield’s VPXL (CompuTrack) as a replacement for Karl Fischer titration.
Greg’s challenge to the room was direct: “If you walk into a lab and you see a Karl Fischer titrator, you should be ringing a bell in your hand.” Why? Because every Karl Fischer titration costs approximately $20–30 in materials and labour. A VPXL analysis costs approximately $3. The instrument is reagent-free — no chemicals, no consumables, no disposal costs. No risk of chemical exposure. Substantially lower cost of ownership. And increasingly, a sustainability narrative that resonates with pharmaceutical manufacturers managing their environmental footprint.
One Smart Labtech team member identified a customer with fifteen Karl Fischer titrators who is considering switching to the VPXL platform — a reference account of transformative potential. If one installation succeeds at this scale, it becomes the proof-of-concept for every similar pharmaceutical quality control laboratory in the region.
Greg’s challenge to the team, however, was not about the product — it was about urgency. “It’s on the list. It’s on the schedule. But when are you going to do it? Why not tomorrow?” He outlined the process clearly: one salesperson and one service engineer visit Brookfield’s Mumbai facility, spend two to three days with the application team, prepare the customer’s sample under guidance, validate the results, build confidence — and then bring the instrument to the customer with a proven, documented methodology. “You have to be there on the front end,” he said. “Every day you don’t go is a day that you lose.”
Competing Against Anton Paar — The Hard Truth and the Workaround
The session’s most honest exchange came when a team member raised the persistent challenge: Smart Labtech is losing RSO and RSX (rheometer) cases to Anton Paar on price. How do you compete?
Greg did not flinch. “It is well known that there is no AMETEK company that is the least expensive brand. We are the leaders. We raise prices every year — for inflation, for supply chain, for all the reasons that exist. That’s not going to change.”
But his answer was not resignation — it was strategy. Rohan elaborated with the three-step methodology: application first, proof of concept second, price third. “If you reach a customer after the specification has already been written around Anton Paar’s instrument, you have already lost,” Rohan said. “You need to be there first — understanding their pain points, discussing their sample, their process. Then you prove it works on their material. Then, and only then, does price become the conversation.”
Greg added an illustrative global example: a chemist at Procter & Gamble’s R&D centre in Mason, Ohio, decades ago built a characterisation method around a Brookfield RST for Head & Shoulders shampoo formulation. That method went into production. Today, every P&G facility making shampoo anywhere in the world uses an RSX — because the specification was written at the formulation stage. “That’s where the selling is,” he said. “Not at the procurement desk.”
For cases where Brookfield is genuinely price-competitive but needs to demonstrate it — trade-in arrangements, special pricing approval through Rohan, creative bundling — all of these options exist. “Don’t just walk away,” Greg said. “Come to us. We’ll work with you. But we have to know about it.”
For government tenders — particularly in markets like West Bengal where tender specifications can be manipulated — Rohan offered a tactical insight: bundle the RSX with a moisture analyser in the specification, creating a combined requirement that Anton Paar’s comparable offering cannot meet at the same price point or with the same completeness.
The Legacy LVT Challenge — SOPs, Collector’s Items, and the Digital Transition
A lively exchange arose around the Brookfield LVT — the legendary analogue viscometer that remains in active use in numerous pharmaceutical and paint industry quality control laboratories. A team member raised the issue: a customer with thirteen LVT systems wanting two more replacements, but balking at the significantly increased price. Switching to the digital DV+ equivalent would require SOP revalidation — a regulatory and organisational burden that many established pharmaceutical manufacturers are understandably reluctant to undertake.
Greg was characteristically direct: “We only keep it around because it’s almost like a collector’s item. That’s what it is. We charge more for it. We don’t make as many of them. We’re trying to convert customers to the DB model.”
Rohan’s practical advice: demonstrate the DV+/DVE alongside the LVT — same spindle, same RPM, same principle — showing the customer that the SOP itself does not need to change. The instrument changes; the methodology does not. Time the demonstration. Show the efficiency gain. For production floor environments where electromagnetic interference is a concern, acknowledge the limitation — and note that the analogue LVT’s resilience in those environments is actually a legitimate technical argument in its favour.
For customers not ready to transition: find out which specific spindle is in their SOP, and quote only that spindle for Teflon coating — rather than the entire spindle set, which can exceed the cost of the instrument itself.
The Software Migration — RheoCAD to DV360
The session’s final substantive topic addressed a pressing operational concern for pharma customers: the migration from RheoCAD (versions up to 2.1.54) to the new DV360 platform, with no direct data migration path between the two systems.
The message from Rohan was clear and needed to be communicated to all affected customers without delay: data from RheoCAD cannot be migrated to DV360 due to fundamental platform architecture differences. Customers must retain their existing RheoCAD installation for historical data access. DV360 begins fresh from the go-live date. As Windows 10 and 11 eventually phase out, RheoCAD will become inoperable — making early DV360 adoption not merely advisable but essential for long-term regulatory compliance.
For customers moving from standard to compliance-grade DV360 (particularly those exporting to the US or Europe under FDA/EMA requirements), the compliance package carries a cost. “It’s not free-of-charge,” Rohan said. “If they’re scaling up to export markets, they need to pay for it. Negotiate, yes — but do not give it away for free.”
The Closing — A Thanks That Meant Something
Greg closed with the same directness with which he had opened — and with something that felt genuinely earned rather than formally obligatory.
“It would be terrible of me if I didn’t thank everybody for your efforts and everything that you do. Because without this team of people sitting here, we wouldn’t be successful. It takes a team. It takes everybody to be successful.”
He had arrived unannounced. He had spoken without notes for over an hour. He had answered uncomfortable questions about pricing, competition, and product obsolescence without deflection. And somewhere in that honesty — in the P&G shampoo story, the Karl Fischer bell-ringing image, the five-opportunities-for-one-RSO pipeline model — he had given the Smart Labtech team something more useful than a product presentation.
He had shown them how to think about the business.
The rest — the calls, the sample visits, the demos, the scheduled appointments — was theirs to execute.
“Every day you don’t go,” Greg had said, “is a day that you lose.”
He was not wrong.
